Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

ClinicalTrials.gov ID: NCT00108836

Public ClinicalTrials.gov record NCT00108836. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 13, 2026, 10:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.

Study identification

NCT ID
NCT00108836
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
400 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2005
Primary completion
Not listed
Completion
Apr 30, 2006
Last update posted
May 19, 2010

2005 – 2006

United States locations

U.S. sites
16
U.S. states
8
U.S. cities
16
Facility City State ZIP Site status
Investigational Site Anaheim California 92801
Investigational Site Los Angeles California 90024
Investigational Site Newport Beach California 92660
Investigational Site Redlands California 92374
Investigational Site San Diego California 92108
Investigational Site Fort Meyers Florida 33712
Investigational Site St. Petersburg Florida 33702
Investigational Site West Palm Beach Florida 33407
Investigational Site Atlanta Georgia 30308
Investigational Site Hoffman Estates Illinois 60194
Investigational Site Oak Brook Illinois 60523
Investigational Site Overland Park Kansas 66211
Investigational Site Dayton Ohio 45408
Investigational Site Portland Oregon 97239
Investigational Site Madison Tennessee 37115
Investigational Site Memphis Tennessee 38119

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00108836, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 19, 2010 · Synced Sep 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00108836 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →